Author

H. Mak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

A. Belcher· 1 shared A. C. Liu· 1 shared A. Carracedo· 1 shared A. Jaklenec· 1 shared A. Jha· 1 shared A. R. Pardeshi· 1 shared C. Thomas· 1 shared D. C. De Fiesta· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Belcher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Machine Learning-optimized system for on demand, pulsatile, photo- and chemo-therapeutic treatment using near-infrared responsive MoS2-based microparticles in a breast cancer model

M. Kanelli, N. M. Bardhan, M. Sarmadi, S. Alsaiari, W. T. Rothwell, A. R. Pardeshi, D. C. De Fiesta, H. Mak, V. Spanoudaki, N. Henning, J. Han, A. Belcher, R. S. Langer, A. Jaklenec

The paper develops a machine learning-optimized system using MoS2 microparticles for pulsatile, photo- and chemo-therapeutic treatment in a breast cancer model, showing increased survival and tumor eradication.

bioRxiv · Apr 16, 2023 · PreprintBioengineering

Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma

S. M. Davidson, J. E. Heyman, J. P. O'Brien, A. C. Liu, D. R. Schmidt, W. J. Israelsen, T. L. Dayton, R. Sehgal, R. Bronson, E. Freinkman, H. Mak, S. Malstrom, G. Bellinger, A. Carracedo, P. P. Pandolfi, , M. G. Vander Heiden

The paper investigates the role of pyruvate kinase isoforms in prostate cancer, finding that Pkm1 suppresses cancer while Pkm2 promotes it, and that a PKM1-like activator can suppress tumor progression.

bioRxiv · May 9, 2021Cancer Biology